Sign inJoin waitlistJoin the waitlist

Naveen Pemmaraju

Director, Leukemia for Cancer Network · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

Co-Section Head of MPNs · University of Texas M D Anderson Cancer Center
Present
Section of Myeloproliferative Neoplasms (MPNs) Clinical Research Center for MPNs · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2008–2011
Internal Medicine
Johns Hopkins Hospital
2005–2008
Univ of Arkansas Coll of Med
2001–2005

Research

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Cancer Discovery · 2019 · 474 citations
Ibrutinib and Venetoclax for First-Line Treatment of CLL
New England Journal of Medicine · 2019 · 426 citations
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
American Journal of Hematology · 2018 · 373 citations

Hagop Kantarjian
236 papers
Naval Daver
224 papers
Tapan Kadia
213 papers
GB
Gautam Borthakur
200 papers
Elias Jabbour
193 papers
Guillermo Garcia-Manero
190 papers
Courtney DiNardo
172 papers
Marina Konopleva
164 papers
Jorge Cortes
110 papers
KS
Koji Sasaki
106 papers · 15 as a resident
Nitin Jain
103 papers · 2 as a fellow
Nicholas Short
102 papers · 7 as a fellow

Clinical trials

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2026–2033
Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
Principal investigator · Recruiting · Phase 1
Pacylex Pharmaceuticals
2025–2026
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2020–2026
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Principal investigator · Completed · Phase 1
M.D. Anderson Cancer Center
2019–2022